PF06447475 - CAS# 1527473-33-1 0197 has been examined against a

has been examined against a panel of 33 protein kinases

Smiles: CN1C=C(C=N1)C1C=CC(=CC=1)S(=O)(=O)N1C=C(/C=C/C(=O)NC2=CC=CC=C2N)C=C1

Moscarella E

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial

3-d]pyrimidin-4-ol

PF06447475 - CAS# 1527473-33-1 0197 has been examined against aPF06447475, CAS No. 1527473 33 1, is a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD) by genome wide association studies (GWAS). The most common LRRK2 mutation, G2019S, which is relatively rare in the total population, gives rise to increased kinase activity. As such, LRRK2 kinase inhibitors are potentially useful in the